we are driven by a vision to end cancer mortality. our company was founded on this vision in 2007. tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer. our broadly applicable product candidates are designed to activate a patient’s immune system against their cancer from within. at the core of our approach is a novel gene therapy platform that utilizes retroviral replicating vectors (rrvs), which are designed to selectively deliver therapeutic genes into the dna of cancer cells. our proprietary platform is designed to fight cancer through a combination of mechanisms of action without the autoimmune toxicities that patients commonly experience with other treatments. in other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ he
Company profile
Ticker
FBRX
Exchange
Website
CEO
Martin Duvall
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Tocagen Inc
SEC CIK
Corporate docs
Subsidiaries
Forte Biosciences Emerald Limited • Forte Biosciences Australia Pty Ltd ...
FBRX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
18 Mar 24
8-K
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
18 Mar 24
8-K/A
Submission of Matters to a Vote of Security Holders
16 Feb 24
8-K
Changes in Registrant's Certifying Accountant
8 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K/A
Submission of Matters to a Vote of Security Holders
26 Sep 23
8-K
Departure of Directors or Certain Officers
20 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Sep 23
DFAN14A
Additional proxy materials by non-management
14 Sep 23
EFFECT
Notice of effectiveness
11 Sep 23
Transcripts
Latest ownership filings
4
BARBARA K FINCK
25 Mar 24
4
Antony A Riley
25 Mar 24
4
Paul A. Wagner
25 Mar 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G
TYBOURNE CAPITAL MANAGEMENT (HK) LTD
14 Feb 24
SC 13G/A
ALGER ASSOCIATES INC
14 Feb 24
SC 13G/A
Farallon Capital Partners, L.P.
14 Feb 24
SC 13D/A
BML Investment Partners, L.P.
11 Jan 24
SC 13D/A
Funicular Funds, LP
9 Jan 24
SC 13D/A
Camac Fund, LP
5 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 46.19 mm | 46.19 mm | 46.19 mm | 46.19 mm | 46.19 mm | 46.19 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.41 mm | 2.59 mm | 3.02 mm | 1.89 mm |
Cash used (since last report) | n/a | n/a | 20.34 mm | 15.45 mm | 18.04 mm | 11.27 mm |
Cash remaining | n/a | n/a | 25.84 mm | 30.73 mm | 28.15 mm | 34.92 mm |
Runway (months of cash) | n/a | n/a | 7.6 | 11.9 | 9.3 | 18.5 |
Institutional ownership, Q3 2023
93.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 41 |
Opened positions | 11 |
Closed positions | 7 |
Increased positions | 6 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 10.98 bn |
Total shares | 34.06 mm |
Total puts | 100.00 |
Total calls | 29.70 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Tybourne Capital Management | 3.62 mm | $2.40 bn |
Farallon Capital Partners | 3.48 mm | $3.52 mm |
Perceptive Advisors | 3.27 mm | $2.16 bn |
Biotechnology Value Fund L P | 2.98 mm | $3.01 mm |
BVF | 2.98 mm | $1.97 bn |
Funicular Funds | 2.03 mm | $0.00 |
Fred Alger Management | 1.84 mm | $1.22 bn |
Alger Associates | 1.84 mm | $1.53 mm |
Farallon Capital Management | 1.81 mm | $1.20 bn |
BML Capital Management | 1.76 mm | $1.17 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Mar 24 | Barbara K Finck | Stock Option Common Stock | Grant | Acquire A | No | No | 0.69 | 175,000 | 120.75 k | 175,000 |
21 Mar 24 | Riley Antony A | Stock Option Common Stock | Grant | Acquire A | No | No | 0.69 | 350,000 | 241.50 k | 350,000 |
21 Mar 24 | Wagner Paul A. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.69 | 1,100,000 | 759.00 k | 1,100,000 |
1 Jan 24 | Wagner Paul A. | Common Stock | Payment of exercise | Dispose F | No | No | 0.8217 | 4,109 | 3.38 k | 1,850,377 |
1 Jan 24 | Wagner Paul A. | Common Stock | Option exercise | Acquire M | No | No | 0 | 31,250 | 0.00 | 1,854,486 |
1 Jan 24 | Wagner Paul A. | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 31,250 | 0.00 | 375,000 |
1 Jan 24 | Hubert C Chen | Common Stock | Payment of exercise | Dispose F | No | No | 0.8217 | 3,073 | 2.53 k | 93,405 |
1 Jan 24 | Hubert C Chen | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,500 | 0.00 | 96,478 |
1 Jan 24 | Hubert C Chen | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 7,500 | 0.00 | 90,000 |